It is with extreme pride that we can share with you the below "Press Release" written by Professor Graeme Stewart AM, Director, Clinical Immunology, Westmead Hospital Director, Centre for Immunology & Allergy Research Westmead Institute for Medical Research
Without our Major Sponsor, Ryde Eastwood Leagues Club, Our ClubsGrant Sponsor, Wenty Leagues Club, Our Annual Sponsor, Griffin Air Conditioning and all our supporters, family & friends this would still be a dream
From The Board of The Adam Gardiner Fund INC. we thank you all
Adam Gardiner Amyloidosis Clinic at Westmead Hospital
invited to join three new clinical trials
Clinical trials are an important means of getting early access for patients to better treatments. Participants in a clinical trial are assured of ongoing treatment after the trial has finished, often 2 years before governments agree to pay for proven new therapies.
Funding through the Adam Gardiner Fund INC. has enabled the team at Westmead to establish capacity to take on the resource-intensive role of a clinical trials centre.
In the past month, 3 pharmaceutical companies have invited the Westmead centre to be a trial site for exciting new therapies. This includes the anti-SAP treatment pioneered by the UK National Amyloidosis Centre and until now tested only in London, Boston and at the Mayo Clinic. Each of the treatments in these trials carry a high level of confidence of being valuable improvements in care, with the anti-SAP treatment being perhaps the most exciting due to its ability to stimulate cells of the immune system to chew up all forms of amyloid, potentially removing it from the organs the amyloid deposits are damaging.
Such invitations depend upon reputation as a centre of expertise with the comprehensive range of resources needed to carry out very complicated trials. The reputation of the Adam Gardiner Westmead Amyloidosis Centre has been developed over the past 11 years as Australia’s first comprehensive, multidisciplinary clinic providing world’s best care to people and families living with Amyloidosis. Clinical trials in this complex group of serious diseases require the knowledge and experience of medical specialists in several fields working in a co-ordinated way as has been established at Westmead over more than a decade. It also requires senior nurses with expertise in the running of complex trials.
Advances in Amyloidosis research are now paying off with new treatments being trialled at a rate well above that for many diseases. In partnership with the Adam Gardiner Fund INC., the Westmead Amyloidosis Clinic is determined to ensure that Australian patients have equal opportunity of access to these advances in medical science at the earliest possible time.